Biopharmaceutical group, Arecor Therapeutics, has announced the appointment of David Ellam as its interim chief financial officer (CFO), effective immediately.

Ellam, a chartered accountant, has over two decades of experience in the life sciences industry.

He has previously held CFO roles at numerous healthcare companies including Juvenescence, a life sciences company developing therapies to modify ageing, and Silence Therapeutics, a biotechnology company.

More recently, Ellam was CFO at Sixfold Bioscience.

Arecor CEO, Sarah Howell, said: “David is a highly experienced finance executive whose life sciences knowledge and broad financial expertise will be highly valuable in supporting the business moving forward including as we continue to execute our strategic initiatives to drive shareholder value. It is my pleasure to welcome him to the Arecor team.”

---